ReviewMolecular biology reports2021
Multidrug-resistant Acinetobacter baumannii as an emerging concern in hospitals.
Review in Molecular biology reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 201 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
201 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Green-Synthesized Silver Nanoparticles Against Acinetobacter baumannii: A Systematic Review of Antibacterial Activity, Mechanisms of Action, Toxicity, and Antibiofilm Effects.MicrobiologyOpen · 2026Pooled it
- Prevalence of colistin resistance in clinical isolates of Acinetobacter baumannii: a systematic review and meta-analysis.Antimicrobial resistance and infection control · 2024Pooled it
- Prevalence of colistin resistance in clinical isolates ofFrontiers in microbiology · 2024Pooled it
- Loss of CsrA inProceedings of the National Academy of Sciences of the United States of America · 2026Article
- A Biological Approach to Antimicrobial Resistance in New and Old Bacterial Pathogens.Pathogens (Basel, Switzerland) · 2026Review
- A Rapid Screening Strategy for Secondary Bacteriophages to Counter Phage Resistance in Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2026Article
- Antibacterial and Immunomodulatory Effects ofInternational journal of molecular sciences · 2026Article
- Wound infections due to factory gunpowder and pyrotechnic explosions in patients with burn injury: risk factors and antimicrobial resistance.BMC infectious diseases · 2026Observational
- Multiplex RPA-CRISPR/Cas12a Assay for Rapid Detection of Class D OXA-Type Carbapenem-ResistantBiosensors · 2026Article
- Combined effect of eravacycline and omadacycline with other antimicrobial agents against Acinetobacter Baumannii.The Journal of antibiotics · 2026Article
- Research Progress on the Quorum Sensing System ofPathogens (Basel, Switzerland) · 2026Review
- Repurposing Fingolimod as an Antibacterial and Antibiofilm Agent against Carbapenem-ResistantACS omega · 2026Article
- Emergence of a high-risk multidrug-resistantMicrobiology spectrum · 2026Article
- Synergistic effects of halo-plaque forming phage cocktails against polymicrobialMicrobiology spectrum · 2026Article
- Article
- Liposomal antimicrobials in the fight against bacterial and fungal pathogens: Clinical successes and development challenges.International journal of pharmaceutics: X · 2026Review
- Antibiotic Resistance and Biofilm Gene Distribution in Colistin-Resistant Acinetobacter baumannii.MicrobiologyOpen · 2026Article
- The role of microbial biosurfactants in enhancing wound repair: a comprehensive review.Folia microbiologica · 2026Review
- High-Resolution Genomic Surveillance of Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2026Article
- Synergistic Inhibition ofMicroorganisms · 2026Article
141 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acinetobacter baumannii has become a major concern for scientific attention due to extensive antimicrobial resistance. This resistance causes an increase in mortality rate because strains resistant to antimicrobial agents are a major challenge for physicians and healthcare workers regarding the eradication of either hospital or community-based infections. These strains with emerging resistance are a serious issue for patients in the intensive care unit (ICU). Antibiotic resistance has increased because of the acquirement of mobile genetic elements such as transposons, plasmids, and integrons and causes the prevalence of multidrug resistance strains (MDR). In addition, an increase in carbapenem resistance, which is used as last line antibiotic treatment to eliminate infections with multidrug-resistant Gram-negative bacteria, is a major concern. Carbapenems resistant A. baumannii (CR-Ab) is a worldwide problem. Because these strains are often resistant to all other commonly used antibiotics. Therefore, pathogenic multi-drug resistance A. baumannii (MDR-Ab) associated infections become hard to eradicate. Plasmid-mediated resistance causes outbreaks of extensive drug-resistant. A. baumannii (XDR-Ab). In addition, recent outbreaks relating to livestock and community settings illustrate the existence of large MDR-Ab strain reservoirs within and outside hospital settings. The purpose of this review, proper monitoring, prevention, and treatment are required to control (XDR-Ab) infections. Attachment, the formation of biofilms and the secretion of toxins, and low activation of inflammatory responses are mechanisms used by pathogenic A. baumannii strain. This review will discuss some aspects associated with antibiotics resistance in A. baumannii as well as cover briefly phage therapy as an alternative therapeutic treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.